<DOC>
	<DOCNO>NCT00578175</DOCNO>
	<brief_summary>The purpose observer blind study provide information vaccine immunogenicity reactogenicity comparison US standard care ( ProQuad® ) administer Hepatitis A vaccine Pneumococcal vaccine .</brief_summary>
	<brief_title>Immunogenicity Safety GlaxoSmithKline Biologicals ' MMRV Vaccine vs. ProQuad® Children 12-14 Months Age</brief_title>
	<detailed_description />
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol . Male female 12 14 month age time first vaccination . Written inform consent obtain parent/guardian subject . Healthy subject establish medical history clinical examination enter study . Have previously receive 3 dos 7valent pneumococcal conjugate vaccine within first year life . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/ administration vaccine foreseen study protocol 30 day prior vaccination 42 day vaccination , except influenza vaccine . Previous vaccination measles , mumps , rubella and/or varicella . Previous vaccination hepatitis A receipt fourth dose pneumococcal conjugate vaccine . History measles , mumps , rubella and/or varicella/zoster disease . Known exposure measles , mumps , rubella and/or varicella/zoster within 30 day prior start study . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination , include human immunodeficiency virus infection . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect serious chronic illness . History neurologic disorder seizure . Uncomplicated febrile convulsion exclusion criterion . Residence household follow person : Newborn infant ( 04 week age ) . Pregnant mother/women negative history chickenpox disease without record vaccination chickenpox . Pregnant woman beyond 28 week gestation regardless varicella vaccination status varicella disease history . Persons know immunodeficiency . Acute disease time enrolment . All vaccine administer person minor illness . Administration polyclonal immunoglobulin and/or blood product six month enter study plan administration study period . Contraindications commercially available vaccine use study ( Havrix® , Prevnar® , ProQuad® ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>14 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Vaccines</keyword>
	<keyword>Rubella</keyword>
	<keyword>Varicella Vaccine</keyword>
	<keyword>Children</keyword>
	<keyword>Humans</keyword>
	<keyword>Mumps</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Measles</keyword>
	<keyword>Combined Vaccine</keyword>
</DOC>